Marc-Andre Kasper
Vice President, Chemistry & Early Discovery Tubulis
Olivier Marcq, PhD, is Vice President of CMC at Tubulis, where he leads chemistry, manufacturing, and controls strategy to advance next‑generation protein‑drug conjugates toward clinical evaluation. He brings over 15 years of leadership experience in bioconjugation therapeutics, spanning roles in R&D, GMP manufacturing, and biologics development. Prior to Tubulis, Olivier held senior positions at companies including Vaxcyte, Pfizer, Astellas Pharma, and Wyeth, and founded his own consulting firm focused on CMC strategy for bioconjugates. He earned his PhD in Chemistry from the Université de Bourgogne in France and is based in Munich
Seminars
Thursday 11th June 2026
Self-Immolative Phosphoramidates to Expand The Payload Scope in Antibody-Drug Conjugates by Delivery of Hydroxy-Containing Drugs
11:30 am
- Explore how payloads of current marketed ADC are limited to three Modes of Action (MoAs): DNA binders, Tubulin- and TOP-I-Inhibitors
- Present novel linker technologies for stable conjugation and traceless release of hydroxy-containing drugs to expand the payload space in ADCs
- Discuss how resulting ADCs are homogenous at high DAR, have excellent linker stability, and exhibit unprecedented in vivo PK and efficacy
Tuesday 9th June 2026
Reviewing Payload Selection to Understand Why Topoisomerase I Payloads Have Seen Success & Looking Forward to Combat Topo1 Resistance
11:30 am
- Identifying the reason behind the successes with Topoisomerase 1 ADCs
- Assessing the clinical and developmental benefits of Topoisomerase 1 ADCs
- Reviewing the emerging challenges with Topoisomerase 1 resistance and what that means for future development
